The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted the vital role of advanced therapies in supporting the UK Government’s goal of becoming a top three global life sciences economy by 2035.
In its latest annual review, CGT Catapult outlines how it is driving progress in the cell and gene therapy industry, enhancing both economic productivity and patient outcomes.
Over the last financial year, the organisation collaborated with 70 companies, 60% of which were UK-based SMEs. These companies collectively raised more than £177m.
Patient access to innovative treatments is also on the rise. As of April, 17 therapies had been approved and reimbursed for use.
In 2024, 9.5% of global advanced therapy clinical trials included UK representation, with nine CGT Catapult-supported companies conducting trials domestically.
Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, said: “Many thanks to our collaborators in industry, healthcare and Government who we have worked with over the past year. Working together, we have delivered partnerships that supported industry growth, and helped ensure the UK maintains its position as a global leader in advanced therapies.”
He added: “The advanced therapies sector, is crucial to driving forward the Government’s mission of sustainable economic growth and improved health.”
